GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imago BioSciences Inc (NAS:IMGO) » Definitions » Cash Flow from Investing

Imago BioSciences (Imago BioSciences) Cash Flow from Investing : $-26.01 Mil (TTM As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Imago BioSciences Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2022, Imago BioSciences spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $65.79 Mil on purchasing investments. It gained $62.50 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Imago BioSciences spent $3.29 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2022.


Imago BioSciences Cash Flow from Investing Historical Data

The historical data trend for Imago BioSciences's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imago BioSciences Cash Flow from Investing Chart

Imago BioSciences Annual Data
Trend Dec19 Dec20 Dec21
Cash Flow from Investing
-2.73 -74.34 -129.27

Imago BioSciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -70.66 -61.08 8.10 30.26 -3.29

Imago BioSciences Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Imago BioSciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2021 is calculated as:

Imago BioSciences's Cash Flow from Investing for the quarter that ended in Sep. 2022 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Imago BioSciences  (NAS:IMGO) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Imago BioSciences's purchase of property, plant, equipment for the three months ended in Sep. 2022 was $0.00 Mil. It means Imago BioSciences spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Imago BioSciences's sale of property, plant, equipment for the three months ended in Sep. 2022 was $0.00 Mil. It means Imago BioSciences gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Imago BioSciences's purchase of business for the three months ended in Sep. 2022 was $0.00 Mil. It means Imago BioSciences spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Imago BioSciences's sale of business for the three months ended in Sep. 2022 was $0.00 Mil. It means Imago BioSciences gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Imago BioSciences's purchase of investment for the three months ended in Sep. 2022 was $-65.79 Mil. It means Imago BioSciences spent {stock_data.stock.currency_symbol}}65.79 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Imago BioSciences's sale of investment for the three months ended in Sep. 2022 was $62.50 Mil. It means Imago BioSciences gained $62.50 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Imago BioSciences's net Intangibles purchase and sale for the three months ended in Sep. 2022 was $0.00 Mil. It means Imago BioSciences paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Imago BioSciences's cash from discontinued investing activities for the three months ended in Sep. 2022 was 0.00 Mil. It means Imago BioSciences paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Imago BioSciences's cash from other investing activities for the three months ended in Sep. 2022 was $0.00 Mil. It means Imago BioSciences paid $0.00 Mil for other investing activities.


Imago BioSciences Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Imago BioSciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Imago BioSciences (Imago BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA, USA, 94080
Imago BioSciences Inc is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).
Executives
Laura G. Eichorn officer: Chief Operating Officer IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Michael Arenberg officer: See Remarks 10260 BUBB ROAD, CUPERTINO CA 95014
Hugh Jr Rienhoff director, officer: Chief Executive Officer IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Amy E. Tapper officer: See Remarks IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Jennifer Peppe officer: See Remarks IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Hsiangyi Chiang officer: Senior Vice President Finance C/O IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c. 10 percent owner C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Clarus Ventures Iii Gp, L.p. 10 percent owner C/O CLARUS VENTURES, 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Iii, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Group Management L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Holdings I/ii Gp L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Holdings Ii L.p. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Laurie Keating director 300 THIRD STREET, CAMBRIDGE MA 02142

Imago BioSciences (Imago BioSciences) Headlines

From GuruFocus

Imago BioSciences to Host Virtual Investor Event

By GuruFocusNews GuruFocusNews 07-06-2022